Core Viewpoint - Huazhang Biopharmaceutical-B (02396) has made its debut on the stock market with an initial share price of HKD 38.2, issuing 17.6488 million shares and raising approximately HKD 600 million in net proceeds. As of the report, the stock has dropped by 11.52% to HKD 33.8, with a trading volume of HKD 103 million [1]. Company Overview - Established in 2012, Huazhang Biopharmaceutical is a biopharmaceutical company headquartered in China, focusing on developing therapies, particularly protein drugs for indications with medical needs and market opportunities [1]. - The company's primary focus is on discovering, developing, and commercializing wound healing therapies, with a pipeline that includes ten candidate products, seven of which are PDGF candidates [1]. Product Pipeline - The two core products are Pro-101-1, aimed at treating burns, and Pro-101-2, intended for diabetic foot treatment, both of which are rhPDGF-BB drugs [1]. - According to a Frost & Sullivan report, as of the last feasible date, there are three PDGF drug pipelines in China, with no approved PDGF drugs available in the market [1]. - All PDGF pipelines are based on the PDGF-BB isoform, with two pipelines belonging to Huazhang Biopharmaceutical, which entered Phase II clinical trials for diabetic foot treatment in February 2022 and is expected to complete patient enrollment for Phase IIb clinical trials for treating second-degree and superficial burns by April 2025 [1].
新股首日 | 华芢生物-B(02396)首挂上市 早盘低开11.52% 公司为中国领先PDGF药物生物制药企业